UBS Lifts Johnson & Johnson Price Target to $320 Amid Improved Outlook

UBS analysts have raised their price target for Johnson & Johnson (JNJ) to $320 from $280, citing an improved outlook. This increase of $40 represents a significant upward revision by the firm.

The current stock price for JNJ is $271.19, having delivered a remarkable 55.73% return over the past year. However, according to InvestingPro analysis, the company appears overvalued at current levels, trading near its 52-week high of $276.47.

UBS analyst Michael Yee issued this updated price target, while maintaining the firm's Buy rating on JNJ. Johnson & Johnson is a diversified healthcare company that manufactures pharmaceuticals, medical devices and consumer health products.